Brief: Abbisko Cayman Says Unit's FGFR Inhibitor ABSK121 Got U.S. FDA's Clinical Trial Approval
01/11/2022 01:05
Nov 1 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* FGFR INHIBITOR ABSK121 OF ABBISKO THERAPEUTICS GRANTED
CLINICAL
TRIAL APPROVAL BY U.S. FDA
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration